Finance

Lists
DEVA:IST
Deva Holding AS
TRY 90.50
-0.88%
(-0.80) 1D
Aug 27, 6:10:00 PM GMT+3  ·   TRY
All symbols
SymbolPriceChange% Change
Generating top insights for DEVA...
Open
TRY 92.70
High
TRY 92.70
Low
TRY 89.60
Mkt. cap
18.10B
Avg. vol.
771.88K
Volume
545.91K
52-wk high
TRY 92.70
52-wk low
TRY 57.50
EPS
-TRY 4.21
Shares outstanding
200.02M
No. of employees
3K
Open
TRY 92.70
High
TRY 92.70
Low
TRY 89.60
Mkt. cap
18.10B
Avg. vol.
771.88K
Volume
545.91K
52-wk high
TRY 92.70
52-wk low
TRY 57.50
EPS
-TRY 4.21
Shares outstanding
200.02M
No. of employees
3K
Profile
DEVA Holding A.Åž. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements. A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas. As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
About Deva Holding AS
CEO-
Employees3.04K
FoundedSep 22, 1958
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in TRY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in TRY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
4.47B
5.49B
5.91B
6.00B
Cost of goods sold
3.02B
3.84B
3.83B
2.82B
Cost of revenue
3.02B
3.84B
3.83B
2.82B
Research and development expenses
264.29M
174.34M
338.10M
480.63M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.30B
1.58B
1.50B
1.68B
Operating expense
1.55B
1.74B
1.80B
1.93B
Total operating expenses
4.58B
5.58B
5.63B
4.75B
Operating income
-102.14M
-89.10M
278.24M
1.25B
Other non operating income
337.87M
185.09M
617.53M
-160.67M
EBT including unusual items
-137.34M
-340.89M
547.01M
527.53M
EBT excluding unusual items
-137.34M
-362.51M
548.03M
527.53M
Income tax expense
-116.52M
1.00B
637.90M
-86.52M
Effective tax rate
84.84%
-294.28%
116.62%
-16.40%
Other operating expenses
-9.80M
-11.48M
-36.46M
-224.42M
Net income
-20.81M
-1.34B
-90.89M
614.05M
Net profit margin
-0.47%
-24.48%
-1.54%
10.23%
Earnings per share
-
-
-
-
Interest and investment income
59.54M
23.47M
105.21M
115.74M
Interest expense
-617.63M
-656.70M
-506.82M
-677.60M
Net interest expenses
-558.09M
-633.23M
-401.62M
-561.86M
Depreciation and amortization charges
-
-
-
-
EBITDA
237.92M
622.26M
686.52M
1.78B
Gain or loss from assets sale
-15.06M
-15.93M
-32.28M
-12.59M
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps